Literature DB >> 33930453

The translational values of TRIM family in pan-cancers: From functions and mechanisms to clinics.

Guo Zhao1, Chuan Liu1, Xin Wen1, Gan Luan2, Longxiang Xie3, Xiangqian Guo4.   

Abstract

Cancer is the second leading cause of human death across the world. Tripartite motif (TRIM) family, with E3 ubiquitin ligase activities in majority of its members, is reported to be involved in multiple cellular processes and signaling pathways. TRIM proteins have critical effects in the regulation of biological behaviors of cancer cells. Here, we discussed the current understanding of the molecular mechanism of TRIM proteins regulation of cancer cells. We also comprehensively reviewed published studies on TRIM family members as oncogenes or tumor suppressors in the oncogenesis, development, and progression of a variety of types of human cancers. Finally, we highlighted that certain TRIM family members are potential molecular biomarkers for cancer diagnosis and prognosis, and potential therapeutic targets.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; Diagnosis; Inhibitor; Prognosis; TRIM; Therapeutic targets

Mesh:

Year:  2021        PMID: 33930453     DOI: 10.1016/j.pharmthera.2021.107881

Source DB:  PubMed          Journal:  Pharmacol Ther        ISSN: 0163-7258            Impact factor:   12.310


  9 in total

1.  Tripartite motif 52 (TRIM52) promotes proliferation, migration, and regulation of colon cancer cells associated with the NF-κB signaling pathway.

Authors:  Yanjiao Guo; Yiming Zhou; Xiaodong Gu; Jianbin Xiang
Journal:  J Gastrointest Oncol       Date:  2022-06

2.  E3 ligase TRIM15 facilitates non-small cell lung cancer progression through mediating Keap1-Nrf2 signaling pathway.

Authors:  Manman Liang; Lijing Wang; Zhengui Sun; Xingwu Chen; Hanli Wang; Lilong Qin; Wenying Zhao; Biao Geng
Journal:  Cell Commun Signal       Date:  2022-05-09       Impact factor: 7.525

Review 3.  JAK/STAT Signaling: Molecular Targets, Therapeutic Opportunities, and Limitations of Targeted Inhibitions in Solid Malignancies.

Authors:  Bilal Rah; Rafiq A Rather; Gh Rasool Bhat; Abdul Basit Baba; Ifra Mushtaq; Muzamil Farooq; Tahira Yousuf; Sadaf B Dar; Sabra Parveen; Rukhsana Hassan; Fozia Mohammad; Iqbal Qassim; Abida Bhat; Shazia Ali; Mahrukh Hamid Zargar; Dil Afroze
Journal:  Front Pharmacol       Date:  2022-03-24       Impact factor: 5.810

4.  OSgc: A Web Portal to Assess the Performance of Prognostic Biomarkers in Gastric Cancer.

Authors:  Longxiang Xie; Qiang Wang; Zhongyi Yan; Yali Han; Xiaoyu Ma; Huimin Li; Lu Zhang; Xianzhe Li; Xiangqian Guo
Journal:  Front Oncol       Date:  2022-03-11       Impact factor: 6.244

Review 5.  Tripartite motif family proteins in inflammatory bowel disease: Mechanisms and potential for interventions.

Authors:  Rirong Chen; Yizhe Tie; Jinyu Lu; Li Li; Zhirong Zeng; Minhu Chen; Shenghong Zhang
Journal:  Cell Prolif       Date:  2022-04-04       Impact factor: 8.755

6.  Comprehensive Analysis of TRIM Family Genes in Hepatitis Virus B-Related Hepatoma Carcinoma.

Authors:  Wei Hu; Dongsheng Liu; Renjie Li; Hong Qian; Wei Qiu; Qingwang Ye; Fanyun Kong
Journal:  Front Genet       Date:  2022-07-07       Impact factor: 4.772

7.  TRIM36 inhibits tumorigenesis through the Wnt/β-catenin pathway and promotes caspase-dependent apoptosis in hepatocellular carcinoma.

Authors:  Qing Tong; Mingyu Yi; Panpan Kong; Lin Xu; Wukui Huang; Yue Niu; Xiaojing Gan; Huan Zhan; Rui Tian; Dong Yan
Journal:  Cancer Cell Int       Date:  2022-09-06       Impact factor: 6.429

8.  The E3 Ligase TRIM4 Facilitates SET Ubiquitin-Mediated Degradation to Enhance ER-α Action in Breast Cancer.

Authors:  Dianwen Han; Lijuan Wang; Li Long; Peng Su; Dan Luo; Hanwen Zhang; Zheng Li; Bing Chen; Wenjing Zhao; Ning Zhang; Xiaolong Wang; Yiran Liang; Yaming Li; Guohong Hu; Qifeng Yang
Journal:  Adv Sci (Weinh)       Date:  2022-07-17       Impact factor: 17.521

Review 9.  The roles and targeting options of TRIM family proteins in tumor.

Authors:  Yuxin Zhang; Wenzhou Zhang; Lufeng Zheng; Qianqian Guo
Journal:  Front Pharmacol       Date:  2022-09-30       Impact factor: 5.988

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.